In the last trading session, 78395.0 shares of the Citius Pharmaceuticals Inc (NASDAQ:CTXR) were traded, and its beta was 1.32. Most recently the company’s share price was $3.30, and it changed around $0.04 or 1.23% from the last close, which brings the market valuation of the company to $27.95M. CTXR currently trades at a discount to its 52-week high of $26.75, offering almost -710.61% off that amount. The share price’s 52-week low was $2.44, which indicates that the current value has risen by an impressive 26.06% since then. We note from Citius Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.12 million shares, with the 3-month average coming to 274.89K.
Citius Pharmaceuticals Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CTXR as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Citius Pharmaceuticals Inc is expected to report earnings per share of -1.25 for the current quarter.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Instantly CTXR has showed a green trend with a performance of 1.23% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.75 on recent trading dayincreased the stock’s daily price by 12.0%. The company’s shares are currently down -17.50% year-to-date, but still down -9.09% over the last five days. On the other hand, Citius Pharmaceuticals Inc (NASDAQ:CTXR) is 27.91% up in the 30-day period. We can see from the shorts that 0.52 million shares have been sold at a short interest cover period of 0.94 day(s).
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Citius Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -84.03 percent over the past six months and at a 24.62% annual growth rate that is well above the industry average of 16.60%.
2 analysts expect Citius Pharmaceuticals Inc to make 2.67M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.90%.
CTXR Dividends
Citius Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in February.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.81% of Citius Pharmaceuticals Inc shares, and 13.17% of them are in the hands of institutional investors. The stock currently has a share float of 14.13%. Citius Pharmaceuticals Inc stock is held by 62.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 6.3845% of the shares, which is about 10.16 million shares worth $5.93 million.
VANGUARD GROUP INC, with 3.9776% or 6.33 million shares worth $3.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 165.58 shares worth $0.55 million, making up 2.14% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 78.32 shares worth around $0.26 million, which represents about 1.01% of the total shares outstanding.
